DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Q.
Right arrow Articles by Halpert, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Q.
Right arrow Articles by Halpert, J. R.

Vol. 30, Issue 1, 86-95, January 2002

Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modeling

Qinmi Wang and James R. Halpert

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas

Understanding the basis of the substrate specificity of cytochrome P450 2B6 (CYP2B6) is important for determining the role of this enzyme in drug metabolism and for predicting new substrates. Pharmacophores were generated for 16 structurally diverse CYP2B6 substrates with Catalyst after overlapping the reaction sites. Two pharmacophores were determined for the CYP2B6 binding site. Both include two hydrophobes and one hydrogen bond acceptor. The three-dimensional structure of CYP2B6 was then modeled based on the crystal structure of CYP2C5. Benzyloxyresorufin and 7-ethoxy-4-trifluoromethylcoumarin, the two lowest Km substrates in the training set, were then docked in the active site of CYP2B6. The pharmacophores were combined with the CYP2B6 model by comparing the docking results and the mapping of the two substrates with the pharmacophores. The results indicated that the active site of CYP2B6 complements the pharmacophores. The pharmacophores and the CYP2B6 model were used in conjunction to predict the Km values of substrates in a test set of five compounds and yielded satisfactory predictions for benzphetamine, cinnarizine, bupropion, and verapamil but not lidocaine. The CYP2B6 model, the pharmacophores, and the combination of the model with these pharmacophores provide insight into the interactions of CYP2B6 with substrates. The pharmacophores may be used as queries to search a database to predict new substrates for CYP2B6 when the reaction site is known (N- or O-dealkylation). For C-hydroxylation, the CYP2B6 model is helpful in evaluating the possible reaction sites in order for the pharmacophores to predict corresponding Km values.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
R. A. Totah, K. E. Allen, P. Sheffels, D. Whittington, and E. D. Kharasch
Enantiomeric Metabolic Interactions and Stereoselective Human Methadone Metabolism
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 389 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. I. Jushchyshyn, J. L. Wahlstrom, P. F. Hollenberg, and L. C. Wienkers
Mechanism of Inactivation of Human Cytochrome P450 2B6 by Phencyclidine
Drug Metab. Dispos., September 1, 2006; 34(9): 1523 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, U. M. Kent, H. Zhang, L. Waskell, and P. F. Hollenberg
The Functional Role of Threonine-205 in the Mechanism-Based Inactivation of P450 2B1 by Two Ethynyl Substrates: The Importance of the F Helix in Catalysis
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 855 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Ramirez, F. Innocenti, E. G. Schuetz, D. A. Flockhart, M. V. Relling, R. Santucci, and M. J. Ratain
CYP2B6, CYP3A4, AND CYP2C19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., September 1, 2004; 32(9): 930 - 936.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, H. Zhang, L. Waskell, and P. F. Hollenberg
Threonine-205 in the F Helix of P450 2B1 Contributes to Androgen 16{beta}-Hydroxylation Activity and Mechanism-Based Inactivation
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 744 - 751.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. A. Ward, J. C. Gorski, D. R. Jones, S. D. Hall, D. A. Flockhart, and Z. Desta
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 287 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Jinno, T. Tanaka-Kagawa, A. Ohno, Y. Makino, E. Matsushima, N. Hanioka, and M. Ando
Functional Characterization of Cytochrome P450 2B6 Allelic Variants
Drug Metab. Dispos., April 1, 2003; 31(4): 398 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. W. Fan, C. Gu, S. A. Marsh, and J. C. Stevens
Mechanism-Based Inactivation of Cytochrome P450 2B6 by a Novel Terminal Acetylene Inhibitor
Drug Metab. Dispos., January 1, 2003; 31(1): 28 - 36.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Spatzenegger, H. Liu, Q. Wang, A. Debarber, D. R. Koop, and J. R. Halpert
Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular Modeling
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 477 - 487.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.